errors to daughter cells. In contrast, the G1 phase represents the period of commitment to cell cycle progression that separates M and S phases as cells prepare for DNA duplication upon mitogenic signals. 1 An important step in the G1/S transition is the inactivation and phosphorylation of the retinoblastoma gene product (Rb), a tumor suppressor gene product important for G1 control, leading to the release of the transcriptional factor E2F1 and the activation of E2F-responsive genes necessary for progression to S phase (such as cyclin E, thymidine kinase). [2] [3] [4] [5] This phosphorylation occurs by the activation of serine/threonine kinases, known as cyclin-dependent kinases (cdks). 6 These key regulators of the cell cycle are enzymes that periodically form complexes with proteins known as cyclins ( Figure 1 ). There are at least nine different cdks (cdk1-cdk9) [6] [7] [8] [9] and at least 15 different cyclins (cyclin A to T). 10, 11 These complexes are in turn regulated by a stoichiometric combination with small inhibitory proteins (see Figure 1 ). These proteins are called cyclin-dependent kinase inhibitors (CKIs). There are two families of CKIs: the INK4 (inhibitor of cdk4) family, p16 ink4a , p15
ink4b , p18 ink4c and p19 ink4d , that specifically inhibit cyclin D-associated kinases and the KIP (kinase inhibitor protein) family, p21 waf1 , and p27
Kip1 and p57
kip2
, that bind and inhibit the activity of cyclin E/cdk2 and cyclin A/cdk2 complexes. 12 For further insight into cell cycle regulation, excellent reviews of cell cycle control have recently been published. 6, 13, 14 Approximately 90% of human neoplasms have abnormalities in some component of the Rb pathway due either to hyperactivation of cdks as a result of amplification/overexpression of positive cofactors, cyclins/cdks, or downregulation of negative factors, endogenous CKIs, or mutation in the Rb gene product. 1, 5 Of interest, hematopoietic malignancies show clear evidence of aberrations in the Rb pathway, for instance, cyclin D1 translocation, in mantle cell lymphoma; loss in endogenous cdk inhibitors such as in leukemias and hyperactivation of cdk4/cdk6 in human T cell leukemia virus type 1 leukemias, among others. [15] [16] [17] [18] [19] [20] [21] [22] Thus, it is theoretically reasonable to test cdk modulators in human clinical trials in patients afflicted with hematopoietic neoplasms.
Several strategies have been conceived to modulate cdk activity for therapeutic intervention. These strategies may be divided into efforts to directly target the catalytic cdk subunit, or to manipulate cdk activity indirectly by affecting the regulatory pathways that govern cdk activity. 23, 24 The first approach or 'direct' chemical inhibitors represents the most immediate opportunity to allow rational design of small molecule cdk inhibitors to interact specifically with the ATP binding site of cdks. [23] [24] [25] [26] [27] [28] Examples of this group include flavopiridol congeners, polysulfates, butyrolactone I, 9-hydroxyellipticine, toyocamycin derivatives, paullones and purine derivatives. The second approach utilizes agents that 'indirectly' modulate the activity of the cdks by altering the expression and synthesis of the cdk/cyclin subunits or the cdk inhibitory proteins (CKIs); by modulating the phosphorylation state of the cdks by targeting CAK, cdc25, wee1/myt1 and by manipulating the proteolytic machinery that regulates the catabolism of cdk/cyclin complexes or their regulators (see review for further detail 23 ).
Flavopiridol

Preclinical pharmacology
Mechanism of action
Flavopiridol, (L86-8275 or HMR 1275) is a semisynthetic flavonoid derived from rohitukine, an alkaloid isolated from a plant indigenous to India (Figure 2 ). Initial studies from our laboratory revealed that flavopiridol could induce cell cycle arrest during either G1 or G2/M, concordant with the ability of flavopiridol to inhibit both cdk2 and cdk1, respectively.
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Studies utilizing purified cdks showed that flavopiridol inhibits cdks 1, 2 and 4 in a competitive manner with respect to ATP, with a Ki of 41 nM. [29] [30] [31] [32] [33] When the crystal structure of cdk2 and deschloro-flavopiridol was resolved, it was evident that flavopiridol binds to the ATP binding pocket, with the benzopyran occupying the same region as the purine ring of ATP. 34 This observation corroborated our prior biochemical studies with the compound. 31 Flavopiridol inhibits all cdks thus far examined (IC 50 ෂ100 nM), with somewhat less potent effect on cdk 7 (cdk -activating kinase), (IC 50 ෂ300 nM). [30] [31] [32] Another interesting aspect of flavopiridols cell cycle regulat-
Figure 2
Chemical structures of flavopiridol and UCN-01.
ory properties is the depletion of cyclin D1, an oncogene that is upregulated in many human neoplasias and, when overexpressed harbors bad prognosis. 35, 36 Carlson et al 37 showed that when MCF-7 human breast carcinoma cell line were exposed to flavopiridol, cyclin D1 protein levels decreased within 3 h. This effect was followed by decline in cyclin D3 with no alteration in cyclin D2 or cyclin E protein levels, the remaining G1 cyclins, leading to loss in cdk4 activity. 37 Cyclin D1 depletion was a consequence of downregulation of cyclin D1 mRNA associated with specific decline in cyclin D1 promoter measured by luciferase reporter assay. 37 Thus, the cyclin D1 transcriptional repression observed with flavopiridol is consistent with the effects of flavopiridol on the mRNA expression of cell cycle genes from yeast cells (see below) and also underscores the conserved effect of flavopiridol on eukaryotic cyclin transcription. 38 In summary, flavopiridol could induce cell cycle arrest by at least three different mechanisms (see Figure 3) : first, by the direct inhibition of cdks, competitive with respect to ATP; second, by preventing necessary threonine 160 phosphorylation of cdks due to inhibition of cdk7/cyclin H, 32, 33 and finally, in the case of the G1, by downregulation of cyclin D1 and cyclin D3, important cofactors for cdk4 and cdk6 activation.
Several lines of evidence determined that flavopiridol has antiangiogenic properties, Brusselbach et al 39 exposed HUVEC human endothelial cells to flavopiridol. Apoptosis was present even in cells that were non-cycling. Kerr et al 40 tested flavopiridol in an in vivo angiogenesis model demonstrating a decrease blood formation in the mouse Matrigel model of angiogenesis. 40 Furthermore, Melillo et al 41 demonstrated that hypoxia-induced VEGF from human monocytes is suppressed by the presence of low nM concentrations of flavopiridol. This effect occurs at the mRNA and protein levels and is due to decrease in VEGF mRNA stability. 41 Thus, it is conceivable that flavopiridol's antitumor activity may also be mediated by antiangiogenic effects. The relationship between these antiangiogenic properties and cdk modulation are being investigated.
Another interesting feature of flavopiridol is the induction of a differentiated phenotype. Lee and coworkers 42 exposed NCI-H358 lung carcinoma cell lines to flavopiridol and roscovitine, both cdk2 inhibitors, or cdk2 antisense constructs;
Figure 3
G1/S arrest by flavopiridol. Asterisk denotes proven targets for flavopiridol-induced G1 arrest. In the case of cyclins, only cyclin D1 and cyclin D3 are affected by this compound. clear evidence of mucinous differentiation along with loss in cdk2 activity was observed. However, each treatment had different effects on cell cycle regulatory expression despite similar differentiated phenotype. 42 To compare the effects of several cdk inhibitors on cDNA expression from yeast cells, Gray et al 38 cells exposed S. cerevisae for 2 h to compound 52 (a potent cdk2/cdk1 inhibitor) and to flavopiridol. Almost 50% of affected transcripts were shared by compound 52 and flavopiridol. These transcripts belong to genes which regulate progression of cell cycle, phosphate and cellular energy metabolism; and GTP or ATP binding proteins. 38 Similar transcriptional effects of flavopiridol on cyclin genes were observed in human cells (see above). Recently, Chao et al 43 demonstrated that flavopiridol inhibits P-TEFb (also known as cdk9/cyclin T) in vitro with a Ki of 3 nM. Interestingly, in contrast with all cdks tested so far, flavopiridol was not competitive with ATP in this reaction. P-TEFb is a required cellular cofactor for the human immunodeficiency virus (HIV-1) transactivator, Tat. As expected from PTEFb inhibition, flavopiridol blocked Tat transactivation of the viral promoter in vitro. Furthermore, flavopiridol blocked HIV-1 replication in both single round and viral spread assays with an IC 50 of less than 10 nM. 43 Thus, this biochemical effect of flavopiridol should be tested in clinical trials of patients with HIV-related malignancies, including HIV lymphomas.
In an effort to test synergistic effects with other compounds, cytotoxic assays with flavopiridol in combination with standard chemotherapeutic agents were performed. 44, 45 Synergistic effects were demonstrated when flavopiridol followed treatment of A549 lung carcinoma cells with paclitaxel, cytarabine, topotecan, doxorubicin, or etoposide. In contrast, in the case of 5-fluorouracil, flavopiridol needs to be present for 24 h previously to be synergistic. Synergistic effects with cisplatin were not schedule-dependent. 45 In other models, the synergism between flavopiridol with cisplatin and/or ␥-irradiation was not demonstrated, however, flavopiridol demonstrated even more potent effects on tumor cells lines that overexpress MDR. 46 
Effects of flavopiridol on hematopoietic preclinical models
Another important feature of flavopiridol's action is the induction of apoptosis. Studies in several laboratories demonstrated that hematopoietic cell lines such as SUDHL-4 (B cell lymphoma) and Jurkat (T cell leukemia/lymphoma) and CLL cell lines were exquisitely sensitive to flavopiridol-induced apoptosis. [47] [48] [49] [50] [51] Furthermore, flavopiridol inhibits the proliferation of several mantle cell lymphomas cell lines, cell lines that carry overexpression of cyclin D1 due to translocation of cyclin D1 with the heavy chain immunobloglulin promoter. 52, 53 The potent antiproliferative effect of flavopiridol was associated with decline in cyclin D1 expression with loss in cdk activity, loss of clonogenicity and apoptosis. 53 These results have stimulated the development of clinical trials of flavopiridol in this specific refractory lymphoma. 23, 54 Another interesting property of flavopiridol is the ability of this compound to induce apoptosis in DNA-damage insensitive cell lines such as HN-30 squamous head and neck cell line. 55 Again, the apoptotic effect was independent of p53 status and was associated with the depletion of cyclin D1. 55 The mechanism(s) by which flavopiridol induces apoptosis have not yet been clarified. Flavopiridol did not modulate topoisomerase I/II activity, a known effector of apoptosis. 49 
Leukemia
Moreover, in some hematopoietic cell lines neither BCL-2/BAX nor p53 appeared to be involved, 49, 51, 56, 57 while in other hematopoietic models, bcl-2 may be downregulated. 50 ,51 Similar p53-independent apoptosis was observed when flavopiridol was tested against a panel of squamous head and neck cell lines. 55 Preliminary evidence from our laboratory demonstrated that flavopiridol-induced apoptosis in leukemia cell lines is associated with early activation of the MAPK protein kinase family (MEK, p38 and JNK). 56 This activation may lead to activation of caspases. 56 As seen in this and other models, caspase inhibitors prevent flavopiridol-induced apoptosis. 48, 56 Recently, Kitada et al 51 showed that in a panel of B-CLL cell lines, flavopiridol downregulated the antiapoptosis proteins XIAP, Mcl-1 and BAG-1. The mechanism(s) of downregulation and relevance for apoptosis are still unknown. It is unclear whether the putative flavopiridolinduced inhibition of cdk activity is required for induction of apoptosis. Intense efforts to understand the mechanism of flavopiridol-induced apoptosis are currently being carried out by several investigators.
Initial studies with flavopiridol administered in a protracted fashion demonstrated that flavopiridol has a cytostatic effect in colorectal (colo 205) and prostate (LnCap/DU-145) carcinoma xenograft models when administered frequently. 58 These results stimulated the initial clinical trials of flavopiridol in humans as a 72-h continuous infusion every 2 weeks 23, 59 (and see below).
Recently, studies from our laboratory have shown that flavopiridol has notable activity in leukemia/lymphoma xenografts when administered as a bolus intravenous schedule, rendering animals tumor free in the HL-60 and AIDS-lymphoma models while infusional flavopiridol in similar models only achieved tumor growth delays. 47 This significant antitumor effect is due to frank apoptosis and was associated with peak flavopiridol plasma concentration ෂ5-8 M. 47 Based on these results, a phase I trial with bolus flavopiridol administration is currently being explored at the NCI (see below).
Human clinical trials with flavopiridol Flavopiridol phase I clinical trials:
Two clinical trials of infusional flavopiridol administered by a 72-h continuous infusion every 2 weeks have recently been completed. 59, 60 Seventy-six patients were treated in the NCI phase I trial. Dose-limiting toxicity (DLT) was secretory diarrhea with a maximal tolerated dose (MTD) of 50 mg/m 2 /day × 3 (see Table 1 ). In the presence of anti-diarrhea prophylaxis, patients were able to be treated at higher doses, allowing a second MTD, 78 mg/m 2 /day × 3. DLTs at the higher dose level (Table 1) consisted of reversible hypotension and a significant pro-inflammatory syndrome (fever, fatigue, local tumor pain and modulation of acute phase reactants). 59 In an effort to understand the pro-inflammatory syndrome, we determined prospectively the plasma concentration of different cytokines before and during flavopiridol infusion. A dose-dependent significant increase in IL-6 was observed (A Senderowicz, manuscript in preparation). How this putative cdk inhibitor modulates cytokine expression is being explored in our laboratory. Another interesting side-effect was the induction of dosedependent reversible lymphocytopenia. No evidence of increased prevalence of infections was observed in this trial. Based on this effect along with the preclinical data in hematopoietic neoplasms, clinical trials of flavopiridol in CLL are ongoing. Some patients, particularly with non-Hodgkin's lymphoma, colon, prostate and kidney cancer showed shrinkage of tumor masses that, in some circumstances, lasted for more than 6 months, including one patient with refractory renal cancer who achieved a partial response. Five patients received flavopiridol for more than 1 year and one patient received flavopiridol for more than 2 years. This potential for 'disease stabilization' noted in this trial is concordant with the preclinical models, where tumor stasis was observed. Plasma flavopiridol concentrations between 300 and 500 nM -active biological concentrations able to inhibit cdk in vitro -were safely achieved during our trial. 59 In a second phase I trial, also exploring the use of a 72-h continuous infusion every 2 weeks, Thomas et al 60 found that the DLT is diarrhea, corroborating the NCI experience. Moreover, plasma flavopiridol concentrations between 300 and 500 nM were also observed. 60 Interestingly, one patient with refractory metastatic gastric cancer achieved a sustained complete response without any evidence disease more than 2 years after discontinuation of flavopiridol.
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Flavopiridol 1-h infusion phase I clinical trial:
In September 1998, we began the first phase I trial of a daily 1-h infusion of flavopiridol for 5 consecutive days every 3 weeks. This dose schedule was based on the striking antitumor results of flavopiridol observed in leukemia/lymphoma and head and neck xenografts. 47, 55 The recommended phase II dose is 37.5 mg/m 2 per day for 5 consecutive days (Table 2) . Dose- limiting toxicities observed at 52.5 mg/m 2 /day are nausea/vomiting, neutropenia, fatigue, and diarrhea. 61 Other (non-dose-limiting) side-effects are 'local tumor pain' and anorexia. To reach higher flavopiridol concentrations, the protocol was amended to administer flavopiridol for 3 days (initially) and then for 1 day only (Table 2 ). These protocol modifications allowed the achievement higher flavopiridol concentrations (ෂ4 M). 61 Unfortunately, the half-life observed in this trial is much shorter (ෂ3 h) than the infusional trial (ෂ10 h). Thus, micromolar concentrations attained in this trial were only maintained for very short periods of time. 61 This shorter half-life may explain the lack of antitumor activity observed in this trial.
Other flavopiridol clinical trials:
A phase 1 trial testing the combination of paclitaxel and flavopiridol demonstrated good tolerability with a dose-limiting pulmonary toxicity. 62 Phase II trials of flavopiridol given as a 72-h continuous infusion with the MTD in the absence of anti-diarrheal prophylaxis (50 mg/m 2 /day) to patients with chronic lymphocytic leukemia, non-small cell lung cancer, non-Hodgkin's lymphoma, and colon, prostate, gastric, head and neck, and kidney cancer, and phase I trials of flavopiridol administered on novel schedules and in combination with standard chemotherapeutic agents are being explored.
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UCN-01
Preclinical pharmacology
Mechanism of action
Staurosporine is a non-specific protein kinase inhibitor that shows cell cycle arrest in transformed and non-transformed cells at 1-100 nM. 67 UCN-01 (7-hydroxystaurosporine; see Figure 2 ) is a staurosporine analogue with higher specificity against several PKC isoenzymes, particularly against the Ca 2+ -dependent protein kinase C (cPKCs) with an IC 50 ෂ30 nM with lower potency against the novel Ca 2+ -independent PKCs (nPKCs) ( IC 50 ෂ500 nM) and no effect against the atypical PKCs. [68] [69] [70] In addition to the effects on PKC, UCN-01 shows prominent effects on cell cycle and antiproliferative activity cdk modulators as therapeutic approaches for hematological malignancies AM Senderowicz 5 in several human tumor cell lines. [71] [72] [73] [74] [75] In contrast, another highly selective potent PKC inhibitor, GF 109203X shows no antiproliferative effect despite similar capacity to inhibit PKC in vitro. 72 Taken together, these results suggest that UCN-01's antiproliferative effect is probably not explained solely by inhibition of PKC.
As demonstrated by different groups, UCN-01 arrest can arrest tumor cells in the G1 phase of the cell cycle 71, [74] [75] [76] [77] [78] It appears that this arrest was accompanied by Rb hypophosphorylation and the accumulation of p21 waf1 and p27 kip1 and appears to be independent of the p53 and Rb status. 75, 78 In seeking to define the mechanism(s) for cell cycle arrest, UCN-01 displayed moderately potent inhibition of immunoprecipitated cdc2 and cdk2 (IC 50 300-600 nm). However, when intact cells were exposed to UCN-01, 'inappropriate activation' of the same kinases occurred. 72 
Effects of UCN-01 on hematopoietic preclinical models
A clear antiproliferative effect characterized by loss of G2/M DNA content and clear evidence of apoptosis was readily observed after 300 nM UCN-01 against a panel of leukemia T cell lines (Jurkat, Molt-3, Molt-4 and Hut-78). 72 These effects were correlated with the inappropriate activation of cdk1 and cdk2 from intact cell lines exposed to UCN-01. 72 Furthermore, Wang et al 79 exposed asynchronously growing CA-46 Burkitt's lymphoma (a cell line with defective p53 function) to ␥-irradiation and these cells, as expected from a cell type defective in the G1/S checkpoint due to loss in p53 function, stopped before mitosis (G2 checkpoint activation). 79 This pause probably promotes DNA repair in order to prevent cells segregating damaged chromosomes. 80 The G2 arrest observed after DNA-damaging agents is due to inactivation of the ratelimiting step for progression from G2 to mitosis, cdc2/cyclin B. 81 However, when CA-46 cells are irradiated first, followed by UCN-01, the 'inappropriate activation of cdc2/cyclin B' induced by UCN-01 72 promotes premature mitosis, also known as 'abrogation of G2 checkpoint' followed by apoptosis. 79 These effects could be partially explained by the inactivation of wee 1, the kinase that negatively regulates G2/M transition. 82 Recently, several groups discovered that UCN-01 targets chk1, a regulatory kinase important for G2 checkpoint control after DNA damage. [83] [84] [85] Thus, UCN-01 directly inhibits cdks, but in cells more potently affects 'upstream' kinases that regulates cdc2 activity. Studies from other groups suggest that not only is UCN-01 able to abrogate the G2 checkpoint induced by DNA-damaging agents but also, in some circumstances, UCN-01 is able to abrogate the S-phase checkpoint induced by similar stimuli. 86, 87 Other investigators have demonstrated that the potent apoptotic effects observed in B-CLL lines was associated with downregulation of the antiapoptosis proteins XIAP, Mcl-1 and BAG-1. 51 The mechanism(s) of downregulation and relevance for apoptosis is still unknown.
Another interesting feature of UCN-01 is the observed increased cytotoxicity in cells that harbor mutated p53. 79 In fact, CA-46 (Burkitt's lymphoma) and HT-29 (colon carcinoma) tumor cell lines, both carrying the p53 mutated phenotype, exposed to UCN-01 displayed significant cytotoxicity. Moreover, MCF-7 cell lines harboring no endogenous p53 due to ectopic expression of the human papillomavirus type-16 E6 protein, showed enhanced cytotoxicity with the combination between DNA-damaging agents, such as cisplaLeukemia tin and UCN-01, compared with the isogenic wild-type MCF-7 cell line. Another interesting effect of UCN-01 is the synergistic effect with standard chemotherapeutic agents including mitomycin C, 5-fluoruracil, BCNU, camptothecin, among others 86, [88] [89] [90] [91] [92] [93] This in vitro experience has stimulated several groups to begin trials of UCN-01 with standard agents (see below).
When UCN-01 is administered by an intraperitoneal or intravenous route antitumor activity is displayed in several human xenografts including MOLT-4, HL-60 leukemia models. 23, 73 Better antitumor effects were observed when UCN-01 was given by protracted exposures. This requirement for longer concentration-time exposure was also observed in in vitro models, obtaining the highest antitumor activity when UCN-01 was present for 72 h. 71 Thus, a clinical trial using a 72-h continuous infusion every 2 weeks was conducted (described below).
Human clinical trials with UCN-01
Based on the antitumor activity observed in preclinical models and unique biochemical features including potent antiproliferative effects in p53-defective cell lines and G2 checkpoint abrogation after DNA damage, we recently completed the first phase I trial of UCN-01 in humans (Table 1) . 94 A surprising effect observed in this initial human experience included an unexpected very prolonged half-life (ෂ600 h), 100 times longer than the half-life observed in preclinical models, probably due to very avid binding to the human plasma protein to alpha-1-acid glycoprotein (AAG). 95, 96 DLTs were nausea/vomiting, symptomatic hyperglycemia and pulmonary toxicity ( Table 1 ). The MTD of UCN-01 using a 72 h continuous infusion schedule was 42.5 mg/m 2 /day. 97 One patient with refractory metastatic melanoma developed a partial response that lasted 8 months. Few patients with leiomyosarcoma, non-Hodgkin's lymphoma and lung cancer demonstrated significant tumor stabilization (у6 months). 97 Of interest, one patient with refractory anaplastic large cell lymphoma (T cell phenotype, alk-expressing) who failed multiple chemotherapeutic regimens including high-dose chemotherapy has no evidence of disease 3 years after the initiation of UCN-01. Another patient with refractory large B cell lymphoma who failed prior high-dose combination chemotherapy protocol-EPOCH-2 had rapidly progressive disease after one cycle of UCN-01 with hepatic and bone marrow failure (thrombocytopenia) requiring immediate chemotherapy. After dose-modified EPOCH without cyclophosphamide, his liver function and thrombocytopenia resolved completely with significant improvement in performance status within 2 weeks after combination chemotherapy. Unfortunately, he developed fungemia with a resistant candida Kruzei strain and expired. Post-mortem examination revealed a pathological complete response after only one cycle of chemotherapy. 98 We feel that this refractory large cell lymphoma patient became 'chemotherapy-sensitive' after only one dose of UCN-01. This observation is consistent with the synergistic effect observed in preclinical models of UCN-01 with several chemotherapeutic agents.
In order to determine 'free UCN-01 concentrations' from body fluids in this infusional trial, several efforts were considered. Plasma ultracentrifugation and salivary concentrations of UCN-01 revealed similar results. At the recommended phase II dose (42.5 mg/m 2 /day over 72 h), concentrations of 'free-salivary' UCN-01 (ෂ111 nm) that may cause G2 checkpoint abrogation can be achieved. Moreover, to assess if plasma from these patients have the potential to abrogate the G2 checkpoint, irradiated MCF-7 cells were exposed to plasma obtained from patients at the end of the infusion demonstrating clear evidence of G2 checkpoint abrogation (A Senderowicz, manuscript submitted for publication). Furthermore, in order to determine the signaling effects of UCN-01 in tissues, the assessment of protein kinase C activity, as measured by immunoblots that only recognize phosphorylated adducin (a known PKC substrate) was used. Clear decline in phospho-adducin content in patients at the 42.5 and 53 mg/m 2 /day levels were determined from bone marrow aspirates and tumor cells abrogation (A Senderowicz, manuscript submitted for publication). Thus, we believe that PKC signaling was modulated in vivo in this trial despite high AAG binding.
Trials with shorter schedules (3 h) of infusional UCN-01 are being conducted. Interestingly, the toxicity profile of shorter infusions is similar to that observed with the 72-h infusion trial.
99,100 However, with shorter infusions, more pronounced hypotension was observed.
99,100 Determination of free UCN-01 and toxicity profiles in these trials are of the utmost importance as higher free concentrations for shorter periods may be more or less beneficial/toxic compared with the free concentrations observed in the 72-h infusion trial.
Based on the unique pharmacological features and anecdotal clinical evidence of synergistic effects in one patient with refractory disease, 98 several combination trials with standard chemotherapeutic agents recently commenced. A phaseI/II trial of gemcitabine followed by 72-h infusional UCN-01 in chronic lymphocytic leukemia started at the NCI. Moreover, a trial of UCN-01 in combination with Ara-C is being conducted at MD Anderson University, Houston, TX, USA. Other studies in combination with cisplatin, 5-fluoruracil, among others, also commenced recently.
Several clinically oriented questions are shared between UCN-01 and flavopiridol, including which is the best schedule (short bolus vs infusion), how to combine with other agents? And what are the best pharmacodynamic endpoints to be followed, along with the specific issue of how to best measure free UCN-01 concentration and how to clinically exploit the G2 checkpoint abrogation induced by UCN-01.
Summary
With the recent understanding of the role of cdks in cell cycle regulation and the discovery that approximately 90% of all neoplasias (including hematopoietic neoplasms) are the result of 'cdk hyperactivation' leading to the abrogation of the Rb pathway, novel cdk modulators are being developed. The first two cdk modulators tested in clinical trials, flavopiridol and UCN-01, demonstrated significant preclinical activity in hematopoietic models. Moreover, in early clinical trials, both compounds demonstrated activity in some patients with NHL. The best schedule to be administered, combination with standard chemotherapeutic agents and demonstration of cdk modulation in tumor samples from patients in these trials are important issues that need to be answered in order to ensure the best possible use of these agents. From a scientific standpoint, these drugs are interesting compounds in continuing to elucidate the connections cdks have to the globally important functions of cell cycle progression, apoptosis, and differentiation.
